The most common human prion disorder is Creutzfeldt-Jakob disease (CJD); it includes sporadic, familial, iatrogenic, and variant subtypes. Diagnostic tests aim at detection with the highest specificity of very small deposits of abnormal prion protein (PrP).
Familial forms are inherited in an autosomal dominant mode through germline mutations of the PrP gene, PRNP. Iatrogenic forms have occurred as a result of exposure to contaminated neurosurgical instruments, dura mater grafts, or transfer of human cadaver pituitary hormones (8 ) . Kuru presented as an epidemic in Papua, New Guinea, in the 1960s and has been linked to cannibalistic rituals. vCJD is zoonotically related to BSE (9, 10 ) . An allelic polymorphism of codon 129 of human PRNP modulates disease susceptibility and clinicopathologic phenotype in CJD (11 ) . Detection of CJD is not possible at the preclinical stage. In symptomatic patients, clinical presentation, electroencephalographic features, brain imaging techniques (12 ) , and 14-3-3 protein analysis in cerebrospinal fluid (13 ) may indicate CJD. Definitive diagnosis requires neuropathologic examination of the brain (14 ) . The recent observation of an increase in sporadic CJD incidence and reports of possible blood transmission of vCJD (15, 16 ) are strong incentives for the development of highly sensitive methods to detect PrP
Res . In this study, we assessed the sensitivity and specificity of immunoquantitative PCR (iqPCR) for the detection of PrP
Res in the brains of CJD patients and compared sample analysis results obtained by iqPCR, immunohistochemistry (IHC), ELISA, and Western blotting.
Materials and Methods case selection
At postmortem examination, brain tissue samples were obtained from 7 patients with sporadic CJD and 7 control individuals. Neuropathologic diagnosis of CJD was based on extensive microscopic review of frontal, temporal, parietal, and occipital cortices; the cingulum, hippocampus, and amygdala; central gray matter; subthalamic nuclei; the brainstem; and the cerebellum. We selected 7 cases with characteristic clinical, histologic, and IHC features of sporadic CJD. Patient age at the time of death ranged from 57 to 81 years (mean, 68 years). Five patients presented with rapidly progressive dementia, 1 with cerebellar ataxia (CJD), and 1 with paresis and paresthesia of the left leg (patient CJD3). All patients later developed myoclonic movements and had abnormal electroencephalograms with periodic sharp wave complexes. There was no family history of demential disorders. Neuropathologic features were characteristic of spongiform encephalopathy, various degrees of spongiform changes, neuronal loss, and gliosis (14 ) . In all 7 cases, IHC analysis with 3 monoclonal antibodies (3F4, KG9, and 4F7) confirmed the presence of PrP
Res deposits, a finding that fulfills current neuropathologic criteria for definite CJD diagnosis (14, 17 ) . The 7 control individuals included 4 patients with neurodegenerative brain diseases and 3 patients with healthy brain histology who died of nonneurologic disorders. This study was approved by the Ethical Committee of the Faculty of Medicine of the University of Liège. The clinical, histologic, and immunohistologic data are summarized in Table 1. ihc For each case, sections (5-m thickness) were cut from formalin-fixed, formic acid-treated, paraffin-embedded brain tissue representative of the middle frontal gyrus cortex, an area where diagnostic surgical biopsies for CJD have been performed (18, 19 ) ; the primary visual cortex (area striata); and the hemispheric cerebellar cortex. Sections were hydrated with graded alcohols and incubated in H 2 O 2 (3 mL/L) for 15 min. They were left in formic acid (96% by weight; Sigma) for 15 min, washed twice in running tap water (10 min each time), and autoclaved for 11 min at 126°C in citrate buffer (pH 6) for antigen retrieval. PrP C digestion was carried out for 5 min in 10 mg/L PK (Sigma) diluted in phosphate-buffered saline as described previously (20 ) . Sections were blocked in normal rabbit serum (1:10 dilution for 1 h; Vector, rinsed, incubated overnight at 4°C with 3 primary monoclonal antibodies against PrP [3F4 (residues 109 -111 hu; 1:50 dilution; Dako), KG9 (residues 140 -180 hu; 1:250 dilution; TSE Resource Center), and 4F7 (residues 140 -160; 1:1000 dilution; Roboscreen)], and then incubated with secondary antibodies (ENVISION; Dako) for 30 min. Immunoreactivity was visualized with 3,3Јdiaminobenzi-dine (DABϩ; Dako). Negative controls were incubations in which the primary antibody was omitted.
elisa, western blots, and iqPCR
Sample preparation. For ELISA, Western blots, and iqPCR, human PrP was extracted by routine optimized purification (Bio-Rad Platelia BSE Kit; cat. no. 355-1102) from frozen brain tissue blocks representative of the middle frontal gyrus. Briefly, nervous tissue (Ϯ350 mg) was homogenized for 45 s, and 500 L of this homogenate was treated with PK for 14 min at 37°C in buffer A. After the reaction was stopped and 500 L of buffer B were added, tubes were centrifuged for 5 min at 20 000g. Immunodetection was performed on pellets previously resuspended in buffer C1 and heated 5 min at 100°C in buffer C1. The positive control was a recombinant cellular human prion protein (Roboscreen).
ELISA. Plastic well surfaces of Immunostrips (Maxisorp; Nunc) or Robostrips ® (Roboscreen) were precoated with 10 mg/L monoclonal antibody 1E5 (Roboscreen) at 6 -8°C overnight. The next day, the wells were emptied, washed 3 times (washing buffer: 50 mmol/L Tris, 150 mmol/L NaCl, 0.5 mL/L Tween 20), blocked for 1 h with 200 L of blocking buffer (washing buffer containing 10 g/L bovine albumin), and rinsed again. The precoated Immunostrips and Robostrips were then sealed in flat bags and stored at 4 -6°C until use. The precoated, saturated strips were incubated with different dilutions (crude and 1:5, 1:10, 1:50, 1:100, 1:500, 1:1000, and 1:5000 dilutions) of human brain extract for 1 h at room temperature. The calibrator (human recombinant PrP) was incubated in the wells at concentrations from 10 mg/L to 10 ng/L. The strips were washed with PBS and then incubated with the biotinylated detection antibody 4F7 (1 mg/L; Roboscreen) for 1 h at room temperature. The wells were again washed 3 times with PBS containing 1 mL/L Tween and 3 times with PBS containing 15 g/L bovine serum albumin. Peroxidase-conjugated streptavidin (Dako; diluted 1:7500) was added to each well and incubated for 30 min at room temperature. After 5 washes in PBS, the residual peroxidase activity was measured by means of chromogenic reaction with a solution containing equal amounts, by volume, of 3,3Ј,5,5Ј-tetramethylbenzidine and H 2 O 2 (BD PharMingen). After incubation for 30 min in the dark at room temperature, the reaction was stopped by addition of 1 mol/L H 2 SO 4 . The absorbance of the reaction mixture was measured at 450 nm (A 450 nm ) with an automatic reader instrument (BioTek ELX800NB).
iqPCR. The iqPCR procedure (Fig. 1 ) was identical to that for ELISA up to the addition of the biotinylated detection antibody 4F7. iqPCR was carried out in Robostrips precoated and saturated with optimized buffer. At each step, the incubation volume was 50 L/well, as it was for the ELISA. The calibrator was used in iqPCR at a dilution range from 1 mg/L to 1 ng/L. After a 1-h incubation with detection antibody, the strips were washed 3 times with PBS containing 1 mL/L Tween and 3 times with PBS containing 15 g/L bovine serum albumin. Briefly, recombinant streptavidin (Roche) was preincubated for 45 min at 4°C with biotinylated reporter DNA in a 1:2 molar ratio (21, 22 ) . The resulting streptavidin-DNA complex was then added to the wells and incubated for 30 min at room temperature. The strips were washed 5 times with PBS and 10 times with distilled water, and then were subjected to PCR. Amplification was carried out in an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) under the following conditions: 500 nL/L SYBR Green PCR Master Mix (Applied Biosystems), 0.3 M each primer, and 380 nL/L water in a total volume of 50 L. The temperature program was as follows: 10 min at 95°C, followed by 40 PCR cycles of denaturation at 95°C for 15 s and 60°C for 1 min for the annealing and extension phases.
SYBR Green is a dye that gives a fluorescence peak when it is intercalated in double-stranded DNA. Amplification curves were analyzed with Sequence Detection System software (Applied Biosystems), and the baseline (threshold) was determined to avoid background signals. The intersection between this threshold and the amplification curve, the cycle threshold (Ct), was plotted on a graph vs the sample dilution. 
Clinical Chemistry
The reporter double-stranded DNA (EMBL sequence access no. AX133313) used is original in that it was built by association of 2 DNA fragments from eukaryotic and prokaryotic origin (21, 22 ) . The primers were designed with Primer Express Software, Ver. 1.0 (Applied Biosystems): forward primer, 5Ј-AAGCCTTGCAGGACATCT-TCA-3Ј; reverse primer, 5Ј-GCCGCCAGTGTGATGGA-TAT-3Ј.
Western blots. For Western blots, after the purification protocol, samples were boiled in loading buffer (Bio-Rad) and subjected to electrophoresis in 12% Tris-glycine gels (10 L of protein extract and 10 L of 2ϫ-concentrated loading buffer per well). Proteins were then blotted on polyvinylidene fluoride (PVDF) membranes that had been blocked overnight at 4°C with the ECL TM Advance Blocking Agent (Amersham Biosciences). Samples were incubated with biotinylated 4F7 (0.1 mg/L) in a solution containing 2 g/L ECL Advance Blocking Agent in Trisbuffered saline containing 1 mL/L Tween for 1 h at room temperature on an orbital shaker. After washing, the membrane was incubated with peroxidase-conjugated streptavidin (Dako; diluted 1:7500) for 1 h at room temperature. Specific bands of prion proteins were revealed by ECL Advance Western blot detection reagents and visualized with a ChemiDoc digital imager (Bio-Rad).
Results ihc
No PrP deposits were detected in the CNS tissue of the 7 control individuals. By contrast, in the tissue samples from the 7 patients with sporadic CJD, PrP
Res deposition was demonstrated by incubation of monoclonal antibodies 3F4 and KG9 with sections from the primary visual cortex and cerebellar cortex.
Spongiform changes, neuronal loss, and gliosis were present in all frontal cortex samples from the 7 patients with sporadic CJD (CJD1 to -7), although with various intensities. As shown in Table 2 , changes were mild in patient CJD3, moderate in patients CJD2, CJD4, CJD5, and CJD6, and severe in patients CJD1 and CJD7.
Using KG9, we identified PrP Res deposits in the frontal cortex of all 7 cases. This result is in accordance with the high sensitivity of KG9 reported by others (20 ) . The pattern of PrP Res deposition was patchy/perivacuolar in patients CJD1, CJD5, and CJD6; the pattern was synaptic in the 4 remaining cases and particularly mild and focal in patients CJD2, CJD3, and CJD4. The antibody 3F4 detected PrP
Res deposits in 6 of 7 cases, with the samples from patient CJD5 remaining negative. The pattern of deposition was patchy/perivacuolar in patients CJD1 and CJD6 and focal/synaptic in the 4 other cases (Fig. 2) . Immunoreactivity for 4F7 was observed in 4 of 7 cases (CJD1, CJD3, CJD4, and CJD6).
western blots
The different protein extracts from the 14 study patients were tested by Western blotting to check for the presence of PrP
Res . No signal was detected in non-CJD patients, whereas PrP
Res was detected in all CJD samples, with different loads, in correlation with the ELISA results. As shown in Fig. 3 , tight PrP
Res levels were observed in cases CJD1 and CJD2. The lowest PrP
Res load was observed in patient CJD4.
standard immunodetection
The human recombinant PrP calibrator was tested by ELISA and iqPCR in the same way as the brain samples. Calibration curves were plotted from a dilution range of the protein for both methods. The detection limits were ϳ1 g/L (defined as 3 ϫ the value for the control ϭ 3 ϫ 0.046) for the ELISA and ϳ100 ng/L for iqPCR. Detection limits of the iqPCR method were defined as the concentration giving a difference of 2.2 Ct (2 SD) lower than that given for the negative control without PrP (Ct ϭ 30); the cutoff thus was 27.8 cycles (Fig. 4) . The sensitivity factor improvement of human recombinant PrP detection was 10. elisa As shown by the A 450 nm values plotted vs sample dilution (Fig. 5) , all control human brains were clearly negative: absorbance was close to 0. In samples from CJD brains, maximum absorbance values were variable (Fig. 5B) . In general, the detection limit for PrP
Res was between dilutions 1:10 and 1:100. The detection limit in this case was (Fig. 6 ) indicated that there was no significant nucleic amplification when the Ct was close to 40. For PK-treated non-CJD samples, the Ct was ϳ30 for all dilutions (Fig. 6A) , which indicates that this is the background value. For all 7 CJD patients, the Ct was dose-dependent ( Fig. 6B) : the lower the PrP concentration, the higher the Ct. The detection limit of iqPCR was much lower than that of ELISA in all cases. In cases CJD1, CJD2, and CJD5, for example, PrP Res was detected in the 1:1000 dilution; the iqPCR detection limit for PrP
Res thus was at least 10-fold lower than the detection limit of the ELISA for all patients (Table 3) .
Discussion
In 2004, Cervenakova and Brown (23 ) reviewed screening tests for the diagnosis of prion diseases, including fluorescent correlation spectroscopy, Seprion ligand, conformationdependent immunoassay, time-resolved fluorescence spectroscopy, and protein misfolding cyclic amplification. They also commented on immuno-PCR as a promising method for detecting PrP
Res at very low concentrations (23 ) .
In a previous study, we showed that bovine PrP Res can be detected with very high sensitivity by iqPCR (21 ). This technology, described previously by Zorzi et al. in patent WO0131056 (22 ) , couples an antibody detection step similar to an ELISA with nucleic acid amplification by a real-time PCR procedure. The detection threshold of iqPCR is lower than classic ELISA for recombinant and infectious bovine PrP (21 ). Clinical Chemistry 51, No. 9, 2005 In the present study, we compared iqPCR with currently used routine methods, such as ELISA, Western blotting, and IHC, for the diagnosis of sporadic CJD cases. Each method showed 100% sensitivity and specificity in our series. With the iqPCR method, however, we detected the presence of PrP
Res at concentrations at least 10-fold lower than with other methods. Like other PCR techniques, iqPCR is hampered by a nonspecific background signal (24 ) . In our data, the background signal was probably generated by nonspecific binding of reagents to the well surface. We have optimized the blocking and washing steps, however, to maintain an acceptable signalto-noise ratio and keep 100% specificity.
Because iqPCR combines 100% specificity with a detection threshold at least 10-fold lower than that of ELISA, iqPCR may improve the detection of minute amounts of PrP Res deposits in tissues and body fluids for diagnostic or sterilization applications.
Brain biopsies are rarely performed in CJD patients when diagnosis of treatable alternatives to spongiform encephalopathy are under serious consideration. In the series of 55 biopsies reported by Brown et al. (18 ) , brain biopsy was diagnostic in 95% of cases later confirmed by autopsy. In our cases, changes indicating spongiform encephalopathy were present in the frontal cortex of all 7 cases, although with mild intensity in 1 case (CJD3). In another, smaller series, Mahadevan et al. (19 ) , using antibodies KG9 and 3F4, detected PrP
Res deposition in only 5 of 8 brain frontal biopsies from CJD patients. In our study, by combining the KG9 and 3F4 antibodies with PK treatment, we detected PrP
Res deposits in 7 of 7 and 6 of 7 cases, respectively. In 4 cases (patients CJD2 to -5), however, deposits were mild and focal, with a synaptic pattern, and could have been missed on an infracentimetric biopsy. Western blotting was confirmatory in most of these cases but was inconclusive in 1 (CJD4), for which ELISA and iqPCR were clearly positive. The main limitation of iqPCR at this stage is the need for fresh or cryopreserved tissue. We are currently adapting the method for use on formalin-fixed, paraffin-embedded material. A recent report (20 ) suggests that well-preserved PrP
Res can be retrieved in useful amounts from such formalin-fixed, paraffin-embedded material. The application of iqPCR to archival material would allow large retrospective studies.
A previous report has shown that macaques infected with extracts of BSE-infected brains have PrP
Res in extra-CNS tissues, such as lymphoreticular tissue in the tonsils, Peyer's patches, and the spleen (15 ) . Moreover, Glatzel et al. (25 ) , using a special phosphotungstate preconcentra- Res accumulates in prion diseases. As reported previously (23 ) , immuno-PCR is a sensitive method that enables detection of small amounts of molecules, but it needs refinement. We have developed an iqPCR method with real-time analysis to improve the technique and avoid time-consuming post-PCR handling (21 ) . We intend in the future to couple the sensitivity of iqPCR with prion protein-scrapie form (PrP Sc ) concentration steps based on phosphotungstic acid precipitation or other means to detect PrP Sc in very low amounts. The recently reported suspicion of transmission of vCJD by blood transfusion (16 ) demonstrates the need for detection methods allowing certification of totally effective decontamination procedures for transfusion material, as well as for neurosurgical and endoscopic instruments. Monitoring of sterilization effectiveness may represent another application of iqPCR.
In conclusion, we have developed iqPCR as a new technique for PrP
Res detection. In our study, iqPCR combined 100% specificity with a detection threshold at least 10-fold lower than that of ELISA. This new method may be useful for the detection of minute PrP
Res deposits in CNS and extra-CNS tissues, such as body fluids.
